Emerging infectious diseases, such as persistent infectious diseases that have not been controlled (i.e., HIV, dengue fever), those increasing in incidence (i.e., flaviviruses, food- and waterborne pathogens), or previously unknown diseases, have impacted populations throughout the world. These diseases require either preventative vaccines or proper therapeutics to mitigate global epidemics from emerging. Recent vaccine and therapeutic candidates have emerged and are moderately successful; however, there is still room for improvement with either long-lasting vaccine efficacy or therapeutics with maximal efficacy and minimal toxicity.
New technologies are necessary for both preventative vaccines and therapeutics for emerging infectious diseases. As these diseases impact populations on a global scale, preventing infection is key. However, when that is not feasible, treatment strategies and specific therapeutics with minimal toxicity and side effects are just as critical in fighting such epidemics. This Research Topic aims to cover current and emerging technologies being explored to prevent or treat infectious diseases, including strategies currently in preclinical or clinical phase studies. We aim to bring together all aspects of research and development of these new technologies and invite vaccinologists, immunologists, pharmacologists, and other multidisciplinary groups to feed knowledge into these growing fields. This research will impact the current landscape of infectious diseases and may also provide interventions against future pandemics.
We welcome the submission of Review and Original Research articles focusing on preclinical and clinical vaccines or therapeutic studies and Perspective and Opinion articles highlighting the gaps in vaccines and therapeutics targeting emerging infectious diseases, including viral or bacterial infections as well as multidrug resistant bacteria. Articles may focus on, but are not limited to, the following subtopics:
• Promising adjuvants in preclinical and clinical vaccine trials
• Promising inhibitors that target infectious diseases in preclinical studies
• Mechanism of action of novel inhibitors or adjuvants
• Formulations that target different sites of action (i.e., mucosal regions)
Emerging infectious diseases, such as persistent infectious diseases that have not been controlled (i.e., HIV, dengue fever), those increasing in incidence (i.e., flaviviruses, food- and waterborne pathogens), or previously unknown diseases, have impacted populations throughout the world. These diseases require either preventative vaccines or proper therapeutics to mitigate global epidemics from emerging. Recent vaccine and therapeutic candidates have emerged and are moderately successful; however, there is still room for improvement with either long-lasting vaccine efficacy or therapeutics with maximal efficacy and minimal toxicity.
New technologies are necessary for both preventative vaccines and therapeutics for emerging infectious diseases. As these diseases impact populations on a global scale, preventing infection is key. However, when that is not feasible, treatment strategies and specific therapeutics with minimal toxicity and side effects are just as critical in fighting such epidemics. This Research Topic aims to cover current and emerging technologies being explored to prevent or treat infectious diseases, including strategies currently in preclinical or clinical phase studies. We aim to bring together all aspects of research and development of these new technologies and invite vaccinologists, immunologists, pharmacologists, and other multidisciplinary groups to feed knowledge into these growing fields. This research will impact the current landscape of infectious diseases and may also provide interventions against future pandemics.
We welcome the submission of Review and Original Research articles focusing on preclinical and clinical vaccines or therapeutic studies and Perspective and Opinion articles highlighting the gaps in vaccines and therapeutics targeting emerging infectious diseases, including viral or bacterial infections as well as multidrug resistant bacteria. Articles may focus on, but are not limited to, the following subtopics:
• Promising adjuvants in preclinical and clinical vaccine trials
• Promising inhibitors that target infectious diseases in preclinical studies
• Mechanism of action of novel inhibitors or adjuvants
• Formulations that target different sites of action (i.e., mucosal regions)